12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

PeptiDream, AstraZeneca deal

PeptiDream partnered with AstraZeneca and its MedImmune LLC unit to discover macrocyclic peptide candidates against targets from the pharma using PeptiDream's Peptide Discovery Platform System (PDPS). PDPS enables incorporation of modified unnatural amino acids into mRNA display peptide libraries. PeptiDream said the...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >